Special <scp>AT</scp>‐rich sequence‐binding protein 2 (<scp>SATB</scp>2) expression is sensitive but may not be specific for osteosarcoma as compared with other high‐grade primary bone sarcomas

Davis, Jessica L.; Horvai, Andrew E.

doi:10.1111/his.12911

Cited by 52 publications

(31 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SATB2 is a useful marker of osteoblastic differentiation . It is highly sensitive but again not entirely specific for osteosarcomatous differentiation . It is best used in the context of seeing morphologic features characteristic of, or strongly suggestive of, osteoid deposition or bone.…”

Section: Discussionmentioning

confidence: 99%

Primary chondro‐osseous melanoma (chondrosarcomatous and osteosarcomatous melanoma)

2017

View full text Add to dashboard Cite

Melanoma can rarely show malignant chondro-osseous differentiation and can cause diagnostic confusion. We report 3 cases of primary melanoma with extensive bone and cartilage matrix. The first case arose in the nasal mucosa of a 72-year-old woman, the second case in the left index finger of a 26-year-old woman and the third case in the left cheek of a 68-year-old woman. In tumors where osseous and chondroid differentiation appear in mucosa and skin, primary melanoma with chondro-osteosarcomatous differentiation should be considered in the differential. Careful histological examination together with clinical correlation and ancillary immunohistochemical studies can ensure the correct diagnosis is made.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary chondro‐osseous melanoma (chondrosarcomatous and osteosarcomatous melanoma)

2017

View full text Add to dashboard Cite

show abstract

“…This pattern of expression has contributed to the argument that SATB2 is a marker for colorectal adenocarcinomas and other hindgut well‐differentiated neuroendocrine tumors [Li et al, ; Kim et al, ]. SATB2 has been shown to be highly expressed in osteosarcoma cells and has been used as a sensitive marker for this type of bone malignancy [Seong et al, ; Davis and Horvai, ;]. In contrast, some reports suggest that SATB2 acts as a tumor suppressor, however no patients with documented SATB2 haploinsufficiency have been reported to have malignancies thus far [Brocato and Costa, ; Guo et al, ; Mansour et al, ; Wu et al, ].…”

Section: Clinical Datamentioning

confidence: 99%

SATB2‐associated syndrome: Mechanisms, phenotype, and practical recommendations

Zárate

Fish

2016

American J of Med Genetics Pt A

123

View full text Add to dashboard Cite

The SATB2‐associated syndrome is a recently described syndrome characterized by developmental delay/intellectual disability with absent or limited speech development, craniofacial abnormalities, behavioral problems, dysmorphic features, and palatal and dental abnormalities. Alterations of the SATB2 gene can result from a variety of different mechanisms that include contiguous deletions, intragenic deletions and duplications, translocations with secondary gene disruption, and point mutations. The multisystemic nature of this syndrome demands a multisystemic approach and we propose evaluation and management guidelines. The SATB2‐associated syndrome registry has now been started and that will allow gathering further clinical information and refining the provided surveillance recommendations. © 2016 The Authors. American Journal of Medical Genetics Part A Published by Wiley Periodicals, Inc.

show abstract

“…43,44 The other type of tumor that shows a high frequency of SATB2 expression is sinonasal carcinoma, seen in 5 of 9 cases (56%) in 1 study.…”

Section: 42mentioning

confidence: 88%

Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary Tract, and Pancreas

Wang¹,

Kim²,

Koo³

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Immunomarkers with diagnostic, therapeutic, or prognostic values have been increasingly used to maximize the benefits of clinical management of patients with neoplastic diseases of the gastrointestinal tract, liver, biliary tract, and pancreas. Objectives.— To review the characteristics of immunomarkers that are commonly used in surgical pathology practice for neoplasms of the gastrointestinal tract, liver, biliary tract, and pancreas, and to summarize the clinical usefulness of immunomarkers that have been discovered in recent years in these fields. Data Sources.— Data sources include literature review, authors' research data, and personal practice experience. Conclusions.— Immunohistochemistry is an indispensable tool for the accurate diagnosis of neoplastic diseases of the gastrointestinal tract, liver, biliary tract, and pancreas. Useful immunomarkers are available to help distinguish malignant neoplasms from benign conditions, determine organ origins, and subclassify neoplasms that are morphologically and biologically heterogeneous. Specific immunomarkers are also available to help guide patient treatment and assess disease aggressiveness, which are keys to the success of personalized medicine. Pathologists will continue to play a critical role in the discovery, validation, and application of new biomarkers, which will ultimately improve patient care.

show abstract

Special AT‐rich sequence‐binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high‐grade primary bone sarcomas

Cited by 52 publications

References 30 publications

Primary chondro‐osseous melanoma (chondrosarcomatous and osteosarcomatous melanoma)

Primary chondro‐osseous melanoma (chondrosarcomatous and osteosarcomatous melanoma)

SATB2‐associated syndrome: Mechanisms, phenotype, and practical recommendations

Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary Tract, and Pancreas

Contact Info

Product

Resources

About